IBR854

· Imbioray (Hangzhou) Biomedicine Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for IBR854, covering 2025-07-28 to 2025-07-28. Get the full timeline:

Most recent: Clinical Trial Update: A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma [Phase 2]